Update on ANCA-associated Vasculitis: from Biomarkers to Therapy

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2019 Jul 14

PMID 31301058

Citations 14

Authors

Martina Tedesco

Maurizio Gallieni

Francesca Pellegata

Mario Cozzolino

Federico Alberici

Affiliations

Soon will be listed here.

Abstract

ANCA-associated vasculitis (AAV) are the prototype of a disease characterised by the presence of a biomarker; ANCA positivity in fact is recorded in 90% of cases of GPA and MPA. The role of ANCA in the management of AAV ranges from diagnostic to prognostic purposes with also therapeutic implications. Changes in clinical practice with the increased use of rituximab have drawn attention to B-cells as a biomarker able to contribute to patient management. Cytokines and other circulating factors, although still at a research stage, may represent future biomarkers of interest or even therapeutic options. From the point of view of renal involvement in AAV, proteinuria and microhematuria are still the biomarkers employed in everyday clinical practice with a proposed role for emerging ones (MCP1, CD163 and CD25). The aim of this review is to discuss the role of well-known biomarkers in everyday clinical management of AAV patients as well as future perspectives for those that are still at a research stage with attention to therapeutic implications.

Citing Articles

Epitope Spreading in Immune-Mediated Glomerulonephritis: The Expanding Target.

Strizzi C, Ambrogio M, Zanoni F, Bonerba B, Bracaccia M, Grandaliano G Int J Mol Sci. 2024; 25(20).

PMID: 39456878 PMC: 11507388. DOI: 10.3390/ijms252011096.

Thrombosis in vasculitis: An updated review of etiology, pathophysiology, and treatment.

Zhu K, Lv F, Hou X, Wang F, Pang L, Zhong M Heliyon. 2024; 10(12):e30615.

PMID: 38975109 PMC: 11225688. DOI: 10.1016/j.heliyon.2024.e30615.

Predictive utility of ANCA positivity and antigen specificity in the assessment of kidney disease in paediatric-onset small vessel vasculitis.

Mann S, Bone J, Bosman E, Cabral D, Morishita K, Brown K RMD Open. 2024; 10(2).

PMID: 38886004 PMC: 11184192. DOI: 10.1136/rmdopen-2024-004315.

ANCA detection with solid phase chemiluminescence assay: diagnostic and severity association in vasculitis.

Renuncio-Garcia M, Calvo-Rio V, Benavides-Villanueva F, Al Fazazi S, Rodriguez-Vidriales M, Escagedo-Cagigas C Immunol Res. 2023; 72(1):128-133.

PMID: 37676628 PMC: 10810966. DOI: 10.1007/s12026-023-09422-z.

Sex disparities in clinicopathological features and outcomes of patients with myeloperoxidase-ANCA-associated vasculitis: a retrospective study of 366 cases in a single Chinese center.

Meng T, Zhu P, Shen C, Ooi J, Eggenhuizen P, Zhou Y Clin Exp Med. 2023; 23(7):3565-3572.

PMID: 37428262 DOI: 10.1007/s10238-023-01115-z.

References

Sinico R, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C . Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005; 52(9):2926-35. DOI: 10.1002/art.21250. View

Alberici F, Martorana D, Bonatti F, Gioffredi A, Lyons P, Vaglio A . Genetics of ANCA-associated vasculitides: HLA and beyond. Clin Exp Rheumatol. 2014; 32(3 Suppl 82):S90-7. View

Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D . Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005; 143(9):632-8. DOI: 10.7326/0003-4819-143-9-200511010-00006. View

Kettritz R . How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. Clin Exp Immunol. 2012; 169(3):220-8. PMC: 3444998. DOI: 10.1111/j.1365-2249.2012.04615.x. View

Hong Y, Eleftheriou D, Hussain A, Price-Kuehne F, Savage C, Jayne D . Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol. 2011; 23(1):49-62. PMC: 3269928. DOI: 10.1681/ASN.2011030298. View

Little M, Al-Ani B, Ren S, Al-Nuaimi H, Leite Jr M, Alpers C . Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One. 2012; 7(1):e28626. PMC: 3256135. DOI: 10.1371/journal.pone.0028626. View

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W . Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2006; 66(2):222-7. PMC: 1798520. DOI: 10.1136/ard.2006.054593. View

Damoiseaux J, Csernok E, Rasmussen N, Moosig F, van Paassen P, Baslund B . Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2016; 76(4):647-653. DOI: 10.1136/annrheumdis-2016-209507. View

Lionaki S, Blyth E, Hogan S, Hu Y, Senior B, Jennette C . Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012; 64(10):3452-62. PMC: 3462364. DOI: 10.1002/art.34562. View

10.

Kemna M, Damoiseaux J, Austen J, Winkens B, Peters J, van Paassen P . ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol. 2014; 26(3):537-42. PMC: 4341475. DOI: 10.1681/ASN.2013111233. View

11.

Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3):221-32. PMC: 3137658. DOI: 10.1056/NEJMoa0909905. View

12.

Fussner L, Hummel A, Schroeder D, Silva F, Cartin-Ceba R, Snyder M . Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis Rheumatol. 2016; 68(7):1700-10. PMC: 7137903. DOI: 10.1002/art.39637. View

13.

Jones R, Cohen Tervaert J, Hauser T, Luqmani R, Morgan M, Peh C . Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010; 363(3):211-20. DOI: 10.1056/NEJMoa0909169. View

14.

Geetha D, Specks U, Stone J, Merkel P, Seo P, Spiera R . Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2014; 26(4):976-85. PMC: 4378104. DOI: 10.1681/ASN.2014010046. View

15.

Geetha D, Hruskova Z, Segelmark M, Hogan J, Morgan M, Cavero T . Rituximab for treatment of severe renal disease in ANCA associated vasculitis. J Nephrol. 2015; 29(2):195-201. DOI: 10.1007/s40620-015-0208-y. View

16.

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P . Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014; 371(19):1771-80. DOI: 10.1056/NEJMoa1404231. View

17.

Gopaluni S, Smith R, Lewin M, McAlear C, Mynard K, Jones R . Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017; 18(1):112. PMC: 5341185. DOI: 10.1186/s13063-017-1857-z. View

18.

Terrier B, Pagnoux C, Perrodeau E, Karras A, Khouatra C, Aumaitre O . Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018; 77(8):1150-1156. DOI: 10.1136/annrheumdis-2017-212768. View

19.

Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A . Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018; 77(8):1143-1149. DOI: 10.1136/annrheumdis-2017-212878. View

20.

Unizony S, Villarreal M, Miloslavsky E, Lu N, Merkel P, Spiera R . Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2015; 75(6):1166-9. PMC: 4908815. DOI: 10.1136/annrheumdis-2015-208073. View